Drug Shortage Report for SABRIL
| Report ID | 189885 |
| Drug Identification Number | 02068036 |
| Brand name | SABRIL |
| Common or Proper name | vigabatrin powder for oral solution |
| Company Name | LUNDBECK PHARMACEUTICALS LLC |
| Market Status | MARKETED |
| Active Ingredient(s) | VIGABATRIN |
| Strength(s) | 500MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | ORAL ORAL |
| Packaging size | Cartons of 50 |
| ATC code | N03AG |
| ATC description | ANTIEPILEPTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-06-01 |
| Actual start date | 2023-07-27 |
| Estimated end date | 2024-05-15 |
| Actual end date | 2024-04-22 |
| Shortage status | Resolved |
| Updated date | 2024-04-23 |
| Company comments | Lundbeck Canada has ceased the sale of Sabril sachets as there may be an alternative available. To help mitigate the ongoing shortage, Health Canada is working with stakeholders to monitor the supply of sachets and has permitted the importation of foreign-authorized vigabatrin sachets. Please see Health Canada’s List of drugs for exceptional importation and sale for information related to the availability of alternative supply. |
| Health Canada comments | |
| Tier 3 Status | Yes |
| Contact Address | SIX PARKWAY NORTH, SUITE 400 DEERFIELD, ILLINOIS UNITED STATES 60015 |
| Company contact information | 1-866-880-4636 canadamedicalinformation@lundbeck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.